The Development of a Protocol for the Use of 5–HT3 Antagonists in Chemotherapy-Induced Nausea and Vomiting

J. Watters; M. Riley; I. Pedley; A. Whitehead; M. Overend; I. Goss; V. Allgar

doi:10.1053/clon.2001.9305

The Development of a Protocol for the Use of 5–HT3 Antagonists in Chemotherapy-Induced Nausea and Vomiting

J. Watters^*
, M. Riley
, I. Pedley
, A. Whitehead
, M. Overend
, I. Goss
, V. Allgar

^*Corresponding author for this work

Peninsula Medical School

Leeds Teaching Hospitals NHS Trust

Research output: Contribution to journal › Article › peer-review

Abstract

The purpose of this study was to evaluate the effectiveness of three 5–HT3 antagonists in routine clinical practice. The ultimate aim was to develop an antiemetic protocol, selecting a single 5–HT3 antagonist. Each of the drugs was studied for a 4–month period and data was collected from patients on nausea, vomiting (both acute and delayed) and side-effects by means of a diary card. A total of 274 patients were enrolled into the study.
Success rates for acute emesis seen over the study period were in excess of 90%. There were no statistically significant differences between any of the three drugs investigated with respect to both acute and delayed nausea and vomiting. Similarly, there was no difference between the three groups for the incidence of constipation, diarrhoea and headache.
Granisetron demonstrated a lesser deviation from the protocol in respect of the number of intravenous doses given to patients.
The study allowed an effective 5–HT3 antagonist protocol to be developed for use in the management of nausea and vomiting in cancer patients.

Original language	English
Pages (from-to)	422-426
Journal	Clinical Oncology
Volume	13
Issue number	6
DOIs	https://doi.org/10.1053/clon.2001.9305
Publication status	Published - Dec 2001

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1053/clon.2001.9305

Cite this

@article{ecf8652ae4ac445fb1a44532eaeba6ff,

title = "The Development of a Protocol for the Use of 5–HT3 Antagonists in Chemotherapy-Induced Nausea and Vomiting",

abstract = "The purpose of this study was to evaluate the effectiveness of three 5–HT3 antagonists in routine clinical practice. The ultimate aim was to develop an antiemetic protocol, selecting a single 5–HT3 antagonist. Each of the drugs was studied for a 4–month period and data was collected from patients on nausea, vomiting (both acute and delayed) and side-effects by means of a diary card. A total of 274 patients were enrolled into the study. Success rates for acute emesis seen over the study period were in excess of 90\%. There were no statistically significant differences between any of the three drugs investigated with respect to both acute and delayed nausea and vomiting. Similarly, there was no difference between the three groups for the incidence of constipation, diarrhoea and headache. Granisetron demonstrated a lesser deviation from the protocol in respect of the number of intravenous doses given to patients. The study allowed an effective 5–HT3 antagonist protocol to be developed for use in the management of nausea and vomiting in cancer patients.",

author = "J. Watters and M. Riley and I. Pedley and A. Whitehead and M. Overend and I. Goss and V. Allgar",

year = "2001",

month = dec,

doi = "10.1053/clon.2001.9305",

language = "English",

volume = "13",

pages = "422--426",

journal = "Clinical Oncology",

issn = "0936-6555",

publisher = "Elsevier Ltd.",

number = "6",

}

TY - JOUR

T1 - The Development of a Protocol for the Use of 5–HT3 Antagonists in Chemotherapy-Induced Nausea and Vomiting

AU - Watters, J.

AU - Riley, M.

AU - Pedley, I.

AU - Whitehead, A.

AU - Overend, M.

AU - Goss, I.

AU - Allgar, V.

PY - 2001/12

Y1 - 2001/12

N2 - The purpose of this study was to evaluate the effectiveness of three 5–HT3 antagonists in routine clinical practice. The ultimate aim was to develop an antiemetic protocol, selecting a single 5–HT3 antagonist. Each of the drugs was studied for a 4–month period and data was collected from patients on nausea, vomiting (both acute and delayed) and side-effects by means of a diary card. A total of 274 patients were enrolled into the study. Success rates for acute emesis seen over the study period were in excess of 90%. There were no statistically significant differences between any of the three drugs investigated with respect to both acute and delayed nausea and vomiting. Similarly, there was no difference between the three groups for the incidence of constipation, diarrhoea and headache. Granisetron demonstrated a lesser deviation from the protocol in respect of the number of intravenous doses given to patients. The study allowed an effective 5–HT3 antagonist protocol to be developed for use in the management of nausea and vomiting in cancer patients.

AB - The purpose of this study was to evaluate the effectiveness of three 5–HT3 antagonists in routine clinical practice. The ultimate aim was to develop an antiemetic protocol, selecting a single 5–HT3 antagonist. Each of the drugs was studied for a 4–month period and data was collected from patients on nausea, vomiting (both acute and delayed) and side-effects by means of a diary card. A total of 274 patients were enrolled into the study. Success rates for acute emesis seen over the study period were in excess of 90%. There were no statistically significant differences between any of the three drugs investigated with respect to both acute and delayed nausea and vomiting. Similarly, there was no difference between the three groups for the incidence of constipation, diarrhoea and headache. Granisetron demonstrated a lesser deviation from the protocol in respect of the number of intravenous doses given to patients. The study allowed an effective 5–HT3 antagonist protocol to be developed for use in the management of nausea and vomiting in cancer patients.

U2 - 10.1053/clon.2001.9305

DO - 10.1053/clon.2001.9305

M3 - Article

SN - 0936-6555

VL - 13

SP - 422

EP - 426

JO - Clinical Oncology

JF - Clinical Oncology

IS - 6

ER -

The Development of a Protocol for the Use of 5–HT3 Antagonists in Chemotherapy-Induced Nausea and Vomiting

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this